For the latest updates on our ongoing response to COVID-19, please click here.

Veklury® Global Marketing Authorization Status

Veklury (remdesivir) has been approved or authorized for temporary use as a COVID-19 treatment in approximately 50 countries worldwide.

  • Argentina
  • Australia*
  • Brazil*
  • Canada*
  • European Union – 30 countries
    (including Iceland, Norway)*
  • Great Britain*
  • Hong Kong*
  • India*
  • Iraq*
  • Israel*
  • Japan
  • Jordan*
  • Lebanon*
  • Russia*
  • Singapore*
  • South Korea*
  • Switzerland*
  • Taiwan*
  • United Arab Emirates*
  • United States

*indicates conditional/provisional approval

  • Bahrain
  • Guatemala
  • Kuwait
  • Mexico
  • Qatar
  • Saudi Arabia
  • Turkey
  • United States (Pediatric patients less than 12 years of age weighing at least 3.5 kg or pediatric patients weighing less than 40 kg and at least 3.5 kg. Learn more here.)

**not including countries approved under EU MAA conditional approval